Clinical Trials Logo
  1. Home
  2. Depressive Disorder
  3. NCT03193112
  4. Details
NCT03193112 Clinical Trial

Melatonin Decreases Eye Pressure in Normotensive Patients

Depressive Disorder Clinical Trial

Official title:
Melatonin Decreases Eye Pressure in Depressive Patients With Normal Intraocular Pressure

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03193112
Other study ID # KahramanmarasSIU
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 16, 2017
Est. completion date June 15, 2018

Study information
Verified date August 2018
Source Kahramanmaras Sutcu Imam University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Agomelatine is a melatonin drug used to treat depressive disorder. Agomelatine may also some effects on ocular pressures. In this study, we aimed to demonstrate that melatonin decreases intraocular pressures when given depressive patients.

Description:

Melatonin has been shown to be effective to decrease intraocular pressure in experimental animal researches. Agomelatine is a melatonin derivative drug approved for the treatment of depression, which is also available in our country. Depending on animal experiments, it can be assumed that agomelatine can decrease intraocular pressure. Demonstrating that agomelatine is effective to reduce eye pressure may give a concurrent treatment of depressive patients with glaucoma. With this it may be possible to treat both diseases at the same time with single drug. In this study, the researchers intended to investigate the changes in ocular tension in normotensive depressive patients treated with agomelatine.

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date June 15, 2018
Est. primary completion date October 15, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 66 Years
Eligibility Inclusion Criteria:

- Depressive patients suitable for Agomelatine therapy for the treatment of their primary disease.

Exclusion Criteria:

- Any past history of ocular surgery, ocular trauma or existing ocular diseases

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Agomelatine 25 MG Oral Tablet
We will treat our patients with Agomelatine tablet of 25 mg.

Locations
Country Name City State
Turkey Kahramanmaras Sutcuimam University Ophthalmology Department Kahramanmaras

Sponsors (1)
Lead Sponsor Collaborator
Kahramanmaras Sutcu Imam University

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary Intraocular pressure mmHg One month
See also
  Status Clinical Trial Phase
Completed NCT01316926 - Paxil CR Bioequivalence Study Brazil Phase 1
Recruiting NCT06187454 - Transcranial Direct Current Stimulation for Depression N/A
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05768126 - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine Phase 4
Completed NCT03219879 - Telephone-administered Relapse Prevention for Depression N/A
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT00069459 - Seasonal Affective Depression (SAD) Study Phase 1
Recruiting NCT05503966 - Combining Antidepressants and Attention Bias Modification in Depression N/A
Recruiting NCT03001245 - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Completed NCT02542891 - European Comparative Effectiveness Research on Internet-based Depression Treatment N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Withdrawn NCT02238730 - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy N/A
Completed NCT01597661 - Bupropion & Cardio Birth Defect (Slone) N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A